Nelarabine

Evidence Level: L5

Predicted Indications: 10

---

Table of Contents

1. Nelarabine
2. Nelarabine: From T-cell Acute Lymphoblastic Leukemia to Relapsing-Remitting Multiple Sclerosis
   1. One-Sentence Summary
   2. Quick Overview
   3. Why is This Prediction Reasonable?
   4. Clinical Trial Evidence
   5. Literature Evidence
   6. EU Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Conclusion and Next Steps
   10. Disclaimer

---

## Pharmacist Assessment Report

Nelarabine: From T-cell Acute Lymphoblastic Leukemia to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Nelarabine is a purine nucleoside antimetabolite originally used to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The TxGNN model predicts it may be effective for Relapsing-Remitting Multiple Sclerosis (RRMS), but this prediction is currently supported by 0 clinical trials and 0 publications, and the underlying rationale flags a direct mechanistic contradiction with the drug’s known neurotoxicity profile.

Quick Overview

Item	Content
Original Indication	T-cell acute lymphoblastic leukemia (T-ALL) / T-cell lymphoblastic lymphoma (T-LBL) (per literature record; no local marketing authorization data available)
Predicted New Indication	Relapsing-Remitting Multiple Sclerosis
TxGNN Prediction Score	99.43%
Evidence Level	L5
EU Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for nelarabine is not available in the current dataset. Based on information found in the supporting literature within this evidence pack, nelarabine is a prodrug that is converted to ara-GTP and acts as a T-cell-selective DNA synthesis inhibitor, exploiting the high deoxycytidine kinase (dCK) to adenosine deaminase/purine nucleoside phosphorylase (ADA:PNP) ratio characteristic of malignant T-lymphoblasts. This selective T-cell cytotoxicity underlies its approved use in T-ALL/T-LBL.

However, the relationship between this cytotoxic mechanism and RRMS runs in the opposite direction of what MS therapy requires. RRMS management centers on immune modulation and myelin protection, whereas nelarabine carries a known black-box warning for severe neurotoxicity, including demyelinating lesions and encephalopathy. Applying a drug whose principal dose-limiting toxicity is demyelination/CNS injury to a demyelinating autoimmune disease is mechanistically contradictory rather than merely under-evidenced — this is explicitly noted in the model’s own repurposing rationale.

For this reason, despite a high TxGNN similarity score, this candidate does not represent a biologically plausible repurposing direction and should not be interpreted as a promising lead without independent confirmatory evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

EU Market Information

Nelarabine currently has no marketing authorization in this jurisdiction (market status: Not Marketed; total licenses: 0). No product-level data is available for reporting.

Cytotoxicity

Nelarabine is an antineoplastic agent (purine nucleoside antimetabolite; approved for T-ALL/T-LBL), so this section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Purine nucleoside antimetabolite; same class as fludarabine, cladribine)
Myelosuppression Risk	Please refer to the SmPC warnings and precautions
Emetogenicity Classification	Please refer to the SmPC warnings and precautions
Monitoring Items	Complete blood count (CBC), neurological examination (given the drug’s known severe neurotoxicity profile), liver and renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Please refer to the SmPC for safety information.

Note: The repurposing rationale for this candidate independently flags that nelarabine carries a known black-box warning for severe neurotoxicity (demyelinating lesions, encephalopathy), which is directly relevant to evaluating its use in a demyelinating disease context such as RRMS.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has no clinical trial or literature support (L5, model prediction only), and the proposed mechanism runs counter to nelarabine’s known neurotoxic/demyelinating liability — a direct conflict with the therapeutic goal in RRMS. There is no basis to advance this candidate at this time.

To proceed, the following is needed:

• Formal mechanism-of-action (MOA) data for nelarabine from DrugBank or the manufacturer
• TFDA/EMA-equivalent labeling data on warnings, contraindications, and neurotoxicity (currently a blocking data gap per this evidence pack)
• Preclinical evidence specifically addressing whether any subpopulation-selective immunomodulatory effect could offset the demyelination risk in an autoimmune CNS disease model
• Independent expert (neurology/oncology) review before any further evaluation stage is considered

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---